Related Experiment Video
Updated: Jun 7, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
Expression of ARC (apoptosis repressor with caspase recruitment domain), an antiapoptotic protein, is strongly
Bing Z Carter1, Yi Hua Qiu, Nianxiang Zhang
1Section of Molecular Hematology and Therapy, Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.
Abstract:
Regulators of apoptosis in acute myeloid leukemia (AML) have been extensively studied and are considered excellent therapeutic targets. Apoptosis repressor with caspase recruitment domain (ARC), an antiapoptotic protein originally found to be involved in apoptosis of cardiac cells, was recently demonstrated to be overexpressed in several solid tumors. To assess its importance in AML, we profiled ARC expression in 511 newly diagnosed AML patients using a validated robust reverse-phase protein array and correlated ARC levels with clinical outcomes. ARC was variably expressed in samples from patients with AML. ARC level was not associated with cytogenetic groups or with FLT-3 mutation status. However, patients with low or medium ARC protein levels had significantly better outcomes than those with high ARC levels: longer overall survival (median, 53.9 or 61.6 vs 38.9 weeks, P = .0015) and longer remission duration (median, 97.6 or 44.7 vs 31.1 weeks, P = .0007). Multivariate analysis indicated that ARC was a statistically significant independent predictor of survival in AML (P = .00013). Inhibition of ARC promoted apoptosis and sensitized cytosine arabinoside-induced apoptosis in OCI-AML3 cells. These results suggest that ARC expression levels are highly prognostic in AML and that ARC is a potential therapeutic target in AML.
Insights
High levels of Apoptosis Repressor with Caspase Recruitment Domain (ARC) protein are linked to poorer outcomes in acute myeloid leukemia (AML). Lower ARC levels indicate better survival and remission duration in AML patients, suggesting ARC as a therapeutic target.
Area of Science:
- Oncology
- Molecular Biology
Background:
- Regulators of apoptosis are key therapeutic targets in acute myeloid leukemia (AML).
- Apoptosis Repressor with Caspase Recruitment Domain (ARC), an antiapoptotic protein, is overexpressed in various cancers.
Purpose of the Study:
- To investigate the prognostic significance of ARC protein expression in newly diagnosed AML patients.
- To evaluate ARC as a potential therapeutic target in AML.
Main Methods:
- ARC protein expression was profiled in 511 AML patients using reverse-phase protein array.
- ARC levels were correlated with clinical outcomes, including overall survival and remission duration.
- Inhibition of ARC was studied in OCI-AML3 cells to assess its effect on apoptosis.
Main Results:
- ARC was variably expressed in AML samples and not associated with cytogenetic groups or FLT-3 mutation status.
- Patients with low or medium ARC levels showed significantly longer overall survival and remission duration compared to those with high ARC levels.
- Multivariate analysis confirmed ARC as an independent predictor of survival in AML (P = .00013).
- ARC inhibition promoted apoptosis and sensitized AML cells to chemotherapy.
Conclusions:
- ARC protein levels are a significant prognostic marker in AML.
- ARC represents a potential therapeutic target for improving AML patient outcomes.
Related Concept Videos
The Intrinsic Apoptotic Pathway
The Extrinsic Apoptotic Pathway
Apoptosis
Abnormal Proliferation
Caspases
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
